Today’s episode will take a deep dive into the science of cancer, asking the hard questions and discussing how regulation may lead to a cure. Our guest. Dr. Steve Worland, has a strong background in pharmaceuticals, research and molecular biology that led to a powerful discussion with Bob and Shelly.
Dr. Steve Worland has served as President and Chief Executive Officer of eFFECTOR Therapeutics and as a member of its Board of Directors since its inception in May 2012. Previously, Dr. Worland served as Chief Executive Officer of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from August 2007 until its acquisition by Roche Holding AG in 2011. Prior to his appointment as Chief Executive Officer of Anadys Pharmaceuticals, Dr. Worland served as its Chief Scientific Officer and President, Pharmaceuticals. Prior to Anadys Pharmaceuticals, Inc., Dr. Worland was Vice President and Head of Antiviral Research at Pfizer Inc. and Vice President at WarnerLambert Co., where he was responsible for worldwide anti-infectives strategy. Dr. Worland has served on the Board of Directors of Tracon Pharmaceuticals, Inc., a biopharmaceutical company, since February 2015. Dr. Worland was an NIH postdoctoral fellow in molecular biology at Harvard University and completed a Ph.D. in Chemistry at the University of California, Berkeley. He received his B.S. with Highest Honors in Biological Chemistry from the University of Michigan.
Selective Translation Regulation Inhibitors
Pipeline of Selective Translation Regulation Inhibitors
Patients and Clinical Trials – eFFECTIVE Therapeutics
Investors – eFFECTOR Therapeutics
Battling Bots League (Be Greater Than Average and Electric Playhouse partnership)
Robot Rumble (in partnership with Cottonwood Mall)
Be Greater Than Average Gift of Learning
Be Greater Than Average Courses
Be Greater Than Average Family Fun!
Be Greater Than Average A Semester of STEM Activities E-Book
Steve Worland, Ph.D., President and Chief Executive Officer
142 North Cedros Avenue, Suite B
Solana Beach, CA 92075
eFFECTOR Therapeutics, Inc. (Linkedin)